All In Biotech

Drug Trial Radar · NCT07937787

A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

Nov 20, 2026

Primary completion

Aug 30, 2027

Study completion Mar 30, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple subcutaneous administration of QLS2406-1. Part A will enroll Chinese adult participants with overweight and obesity, and Part B will enroll participants with obesity.

Conditions

  • Overweight and Obesity
  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Interventions

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously.

  • PlaceboDrug

    Placebo will be administered as a single dose via subcutaneous injection.

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously.

  • PlaceboDrug

    Placebo will be administered as a single dose via subcutaneous injection.

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously.

  • PlaceboDrug

    Placebo will be administered as a single dose via subcutaneous injection.

  • QLS2406-1 injectionDrug

    Administered subcutaneously

  • PlaceboDrug

    Placebo will be administered as a single dose via subcutaneous injection.

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously.

  • PlaceboDrug

    Placebo will be administered as a single dose via subcutaneous injection.

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

  • PlaceboDrug

    Placebo will be administered by subcutaneous injection once weekly (QW).

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

  • PlaceboDrug

    Placebo will be administered by subcutaneous injection once weekly (QW).

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

  • PlaceboDrug

    Placebo will be administered by subcutaneous injection once weekly (QW).

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW).

  • PlaceboDrug

    Placebo will be administered by subcutaneous injection once weekly (QW).

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

  • PlaceboDrug

    Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

  • QLS2406-1 injectionDrug

    QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W).

  • PlaceboDrug

    Placebo will be administered by subcutaneous injection every 2 weeks (Q2W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: Baseline to Day 71

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.